Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evaxion Biotech ( (EVAX) ) has shared an announcement.
On April 16, 2026, Evaxion A/S held its Annual General Meeting at its offices in Denmark, where shareholders approved the 2025 Annual Report and passed all proposals put forward by the Board of Directors. The meeting also confirmed the re-election of four board members and brought a new director, Jens Bitsch Nørhave, onto the board, with minutes made available on the company’s website, signaling continuity in governance as the company advances its AI-driven vaccine pipeline.
The AGM decisions reinforce Evaxion’s existing strategic direction and leadership structure at a time when the company is progressing multiple clinical-stage vaccine candidates for cancer and infectious diseases. For investors and other stakeholders, the approvals and board composition suggest stability in oversight and support for ongoing development efforts based on its AI-Immunology platform.
The most recent analyst rating on (EVAX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Copenhagen-based clinical-stage TechBio company that develops novel vaccines using its proprietary, clinically validated AI-Immunology platform. The technology applies artificial intelligence to decode the human immune system, supporting rapid target discovery, drug design and development of cancer and infectious disease vaccine candidates, including both personalized and off-the-shelf products addressing high unmet medical needs.
Average Trading Volume: 42,985
Technical Sentiment Signal: Sell
Current Market Cap: $34.53M
For detailed information about EVAX stock, go to TipRanks’ Stock Analysis page.